It is incredibly important for these assessments to consider the context of the therapy, rather than just the clinical benefit that it brings, explained Paul Melmeyer, director of Federal Policy, National Organization for Rare Disorders.
Paul Melmeyer: Value Assessments Need to Take Into Account Unique Characteristics of a Disease
It is incredibly important for these assessments to consider the context of the therapy, rather than just the clinical benefit that it brings, explained Paul Melmeyer, director of Federal Policy, National Organization for Rare Disorders.
0 Comments